The Booty Report

Avast ye scallywags! GLP-1 Agonists and SGLT2 Inhibitors be not raisin' the flag o' autoimmune risk, arrr!

2024-03-04

Arrr, ye scallywags with type 2 diabetes, fear not! The lubbers prescribed GLP-1 or SGLT2 were no more likely to catch the dreaded autoimmune disease than those with DPP-4! Aye, 'tis good news from the Medscape Medical News, so drink up me hearties, yo ho!

Arrr matey, listen up ye scallywags! It be said that patients sailin' the treacherous waters of type 2 diabetes, and takin' their prescribed GLP-1 receptor agonists or SGLT2 inhibitors, need not fear the cursed affliction of autoimmune disease! Aye, the wise scribes at Medscape Medical News have declared that those takin' these potions do not face a greater risk of such a malady compared to those takin' the DPP-4 inhibitors.
So fear not, me hearties! Ye can continue on yer medication journey without worryin' about fallin' prey to the nefarious autoimmune disease. The seas be safe, at least in this regard, for those who choose the path of GLP-1 receptor agonists or SGLT2 inhibitors. The wise doctors have spoken, and their words be as true as a pirate's promise.
So raise a tankard of grog to this good news, me mateys! Let the sails of relief billow in the wind, and let the parrots of worry fly off into the sunset. Ye be safe from the clutches of autoimmune disease, thanks to the wonders of modern medicine. Fair winds and smooth sailin', me hearties!

Read the Original Article